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Conclusion: The MLS index is a new easy and practical method for assessment of mitral
stenosis severity.
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Objectives: The single balloon (SB), that is the less expensive technique to perform
mitral balloon (MBV) valvuloplasty. This study aimed to demonstrate that MBV with SB
Balt has similar outcome and long-term follow-up (FU) than MBV performed with the
Inoue worldwide accepted technique.
Methods: From 1987 to 12/31/2011 a total of 526 procedures were performed, being
312 procedures with a FU, 56 (17.9%) with Inoue balloon (IB), the IB group (IBG) and
256 (82.1%) SB Balt group (SBG). The mean FU in IBG was 3327 (2 to 118) and in
SBG 5533 (1 to 198) months (P0.0001). Univariate analysis and multivariate Cox
analysis were utilized to determine independent predict variables of survival and event free
survival (EFS) in both technique groups and major events were (death, cardiac surgery and
new MBV).
Results: In IBG and SBG there were: female 42 (75.0%) and 222 (86.7%) procedures,
(P0.0276), mean age 37.310.0 (19 to 63) and 38.012.6 (13 to 83) years (P0.7138),
sinus rhythm 51 (91.1%) and 215 (84.0%), (P0.1754), echo score (ES) 7.61.3 (5 to
10) and 7.21.5 (4 to 14) points (P0.0528), echo mitral valve area (MVA) pre-MBV
0.960.18 and 0.930.21 cm2 (P0,2265). Post-MBV mean MVA (Gorlin) were
2.000.52 and 2.020.37 cm2 (P0.9550) and at the end of the FU there were: echo
MVA 1.710.41 and 1.540.51 cm2 (P0.0552), new severe mitral regurgitation in 5
(8.9%) and 17 (6.6%) patients (P0.5633), new MBV in 1 (1.8%) and 13 (5,1%),
(P0.4779), mitral valve surgery in 3 (5.4%) and 27 (10.4%), (P0.3456), deaths 2
(3.6%) and 11 (4.3%) deaths, (P1.000), being cardiac deaths 1 (1.8%) and 9 (3.5%),
(p1.0000), major events 5 (8.9%) and 46 (18.0%), (P0.1449). In univariate analysis
and multivariate Cox analysis the SB or IB technique used do not predict survival or
EFS and independent risk factors to survival (multivariate Cox analysis with 2 models
with 5 and 6 variables) were: age50 years (P0.016, HR0.233, 95% IC 0.071-0.764),
ES8 (P0.001, HR0.105, 95% IC 0.34-0.327), MBV dilatation area (P0.001, HR
16.838, 95% IC 3.353-84.580) and mitral valve surgery in the FU (P0.001, HR0.152,
95% IC 0.050-0.459) and to EFS: prior commissurotomy (P0.012, HR0.390, 95%
IC 0.187-0.813) and post-MBV MVA 1.50 cm2 (P0.001, HR7.969, 95% IC
3.413-18.608).
Conclusions: MBV with SB and IB were equally efficient with similar survival and EFS
in the FU. Independent predictors of survival were: age 50 years, ES 8 points, MBV
dilatation area and mitral valve surgery in the FU and of event EFS: prior commissur-
otomy and post-MBV MVA 1.50 cm2.
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Background: To report the short-term clinical outcomes of patients with severe mitral
valve regurgitation undergoing mitral valve repair.
Methods: Four hundred forty patients who underwent mitral valve repair between 2003
to August 2012 in our Institution were identified by using a Society of thoracic Surgeon
(STS) standardized database. We excluded those patients who had previous coronary
artery bypass surgery or valve surgery or endocarditis from the study. The STS mortality
risk sore 3 was used as a cutoff point to define the study group.
Results: Three hundred fifty nine patients with STS mortality risk score lower than 3
were included in the analysis. Observed 30-day mortality and other major clinical
outcomes and predicted outcomes are presented in the following table.
Major Postoperative Clinical Outcomes after Mitral Valve Repair.
Observed
Outcomes
(N359)
STS
Predicted
Outcomes
Mortality (%) 2 (0.6) 0.6
Stroke (%) 4 (1.1) 1.0
Renal-failure (%) 1 (0.3) 2.0
Total ICU hours 43.265.7
Prolonged
ventilation (%)
21 (5.8) 5.7
LOS (days) 5.94.5
Postoperative atrial
ﬁbrillation (%)
100 (27.9)
Total PRBC (ml) 301.5581.8
Readmission to
hospital (%)
31 (8.6)
Moderate or Severe
postoperative
mitral valve
regurgitation (%)
4 (1.1)
STS Predicted
Morbidity or
Mortality (%)
10.8
Conclusions: Our single center experience of isolated mitral valve repair in patients with
STS mortality score lower than 3 is generally in concordance with the predicted STS
outcome rates. The postoperative mitral regurgitation was lower than reported rates in
published articles.
Other
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Objective: We conducted a prospective study of the clinical outcomes and health-related
quality-of-life after implantation of the CorCap cardiac support device (Acorn Cardio-
vascular Inc.) for dilated cardiomyopathy.
Methods: The CorCap was implanted in case of dilated cardiomyopathy (left ventricular
end-diastolic diameter 60 mm. and 80 mm., left ventricular ejectionfraction 30%),
symptoms of heart failure (NYHA class III or IV) despite maximal medical therapy, and
good renal, pulmonary and hepatic functions. Echocardiographic follow-up and evalua-
tion with the SF-36 questionnaire were performed. An average 25.1 4.3 follow-up was
available.
Results: Forty patients were included. A statistically significant improvement was
evident in mean left ventricular ejection fraction, end-diastolic diameter, end-diastolic
volume and volume index, end systolic diameter, end-systolic volume and volume index,
left ventricular sphericity index at the last follow-up vs. baseline. The cumulative mortality
was 10% (no follow-up deaths after the 1st postoperative year). The average physical
health domain scores (physical functioning, role physical, general health) were statistically
improved. Average mental health domain scores were also increased. Concomitant mitral
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